Literature DB >> 6456249

Enhancement of immune responses and possible inhibition of suppressor cells by aclacinomycin A.

M Ishizuka, T Takeuchi, T Masuda, S Fukasawa, H Umezawa.   

Abstract

Antitumor antibiotics were examined as possible candidates that possess activity which inhibits preferentially suppressor cells in comparison with effector cells. In screening for such compounds among known antibiotics, aclacinomycin was found to augment antibody formation and delayed-type hypersensitivity in mice over a wide concentration range. The addition of aclacinomycin to mouse spleen cell cultures also enhanced antibody formation in vitro. The generation of suppressor cells or the suppressor activity per se in mice immunized with high doses of SRBC was reduced by aclacinomycin. These results suggest that the drug may possibly inhibit suppressor cells selectively. The administration of aclacinomycin at ow doses exhibited antitumor effects on IMC carcinoma; the effect was not dose-dependent.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6456249     DOI: 10.7164/antibiotics.34.331

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  3 in total

Review 1.  Immunomodulators isolated from microorganisms.

Authors:  Z Vanĕk; J Matĕjů; E Curdová
Journal:  Folia Microbiol (Praha)       Date:  1991       Impact factor: 2.099

2.  Effect of anticancer agents neothramycin, aclacinomycin, FK-565 and FK-156 on the release of interleukin-2 and interleukin-1 in vitro.

Authors:  K Ahmed; J L Turk
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide.

Authors:  M Hosokawa; Y Sawamura; T Morikage; F Okada; Z Y Xu; K Morikawa; K Itoh; H Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.